PMID- 20518806
OWN - NLM
STAT- MEDLINE
DCOM- 20110603
LR  - 20221207
IS  - 1463-1326 (Electronic)
IS  - 1462-8902 (Linking)
VI  - 12
IP  - 6
DP  - 2010 Jun
TI  - Dapagliflozin treatment in patients with different stages of type 2 diabetes 
      mellitus: effects on glycaemic control and body weight.
PG  - 510-6
LID - 10.1111/j.1463-1326.2010.01216.x [doi]
AB  - AIM: Dapagliflozin is a stable, competitive, reversible, and highly selective 
      inhibitor of sodium-glucose co-transporter 2, the major transporter responsible 
      for renal glucose reabsorption. With an insulin-independent mechanism of action, 
      dapagliflozin is currently being developed for the treatment of type 2 diabetes 
      mellitus (T2DM). This work aims to compare the efficacy of dapagliflozin, as 
      measured by the change in hemoglobin A1c concentration (A1c) and body weight, and 
      to determine the pharmacodynamic effects of dapagliflozin, as measured by urinary 
      glucose excretion in early-stage and late-stage T2DM patient populations. 
      METHODS: A total of 151 early-stage patients and 58 late-stage patients with T2DM 
      randomly assigned 10 or 20 mg once daily (QD) dapagliflozin treatment or placebo 
      for 12 weeks from two phase 2 studies were included in the analysis. A1c, body 
      weight, and urinary glucose were compared between the two patient populations. 
      RESULTS: Compared with the early-stage population, patients in the late-stage 
      population had a longer duration of T2DM and higher baseline levels of A1c, body 
      weight, fasting plasma glucose, and urinary glucose excretion. After 12 weeks of 
      dapagliflozin treatment, A1c reduction, weight loss, and increased urinary 
      glucose excretion from baseline were observed in both populations. Baseline A1c 
      level impacted the A1c reduction after dapagliflozin treatment with a comparable 
      effect in patients with early and late stage disease. Late-stage patients had 
      greater reduction in body weight. There was no statistically significant 
      difference in the amount of urinary glucose excretion between the early-stage and 
      late-stage patients. CONCLUSIONS: Dapagliflozin treatment at 10 and 20 mg QD for 
      12 weeks resulted in significant improvement in glycaemic control and body weight 
      reduction in both early-stage and late-stage patients with T2DM. The findings 
      suggest that dapagliflozin could be a promising treatment option for a wide range 
      of patients with T2DM.
FAU - Zhang, L
AU  - Zhang L
AD  - Research and Development, Bristol-Myers Squibb, Princeton, NJ, USA. 
      liping.zhang3@bms.com
FAU - Feng, Y
AU  - Feng Y
FAU - List, J
AU  - List J
FAU - Kasichayanula, S
AU  - Kasichayanula S
FAU - Pfister, M
AU  - Pfister M
LA  - eng
PT  - Clinical Trial, Phase II
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - England
TA  - Diabetes Obes Metab
JT  - Diabetes, obesity & metabolism
JID - 100883645
RN  - 0 (Benzhydryl Compounds)
RN  - 0 (Blood Glucose)
RN  - 0 (Glucosides)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Sodium-Glucose Transporter 2)
RN  - 1ULL0QJ8UC (dapagliflozin)
SB  - IM
MH  - Benzhydryl Compounds
MH  - Blood Glucose/*drug effects
MH  - Body Weight/*drug effects
MH  - Diabetes Mellitus, Type 2/*drug therapy
MH  - Female
MH  - Glucosides/*pharmacology/therapeutic use
MH  - Glycated Hemoglobin/*drug effects/urine
MH  - Humans
MH  - Hypoglycemic Agents/administration & dosage/*pharmacology
MH  - Male
MH  - Middle Aged
MH  - Sodium-Glucose Transporter 2/administration & dosage/*pharmacology
MH  - Weight Loss
EDAT- 2010/06/04 06:00
MHDA- 2011/06/04 06:00
CRDT- 2010/06/04 06:00
PHST- 2010/06/04 06:00 [entrez]
PHST- 2010/06/04 06:00 [pubmed]
PHST- 2011/06/04 06:00 [medline]
AID - DOM1216 [pii]
AID - 10.1111/j.1463-1326.2010.01216.x [doi]
PST - ppublish
SO  - Diabetes Obes Metab. 2010 Jun;12(6):510-6. doi: 10.1111/j.1463-1326.2010.01216.x.